Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.

Journal of gastroenterology and hepatology - 1 Feb 2015

Yokoyama Satoe, Kawakami Yoshiiku, Imamura Michio, Hayes C Nelson, Kohno Hiroshi, Kohno Hirotaka, Tsuji Keiji, Aisaka Yasuyuki, Kira Shinsuke, Yamashina Keitarou, Nonaka Michihiro, Takahashi Shoichi, Moriya Takashi, Kitamoto Mikiya, Aimitsu Shiomi, Nakanishi Toshio, Kawakami Hiroiku, Chayama Kazuaki

Abstract excerpt

BACKGROUND AND AIM: Chronic hepatitis C genotype 2 patients show high susceptibility to pegylated interferon plus ribavirin therapy (PEG/RBV). However, the differences in response to therapy between genotypes 2a and 2b, and the efficacy of prolonged therapy for refractory patients have not been evaluated. We investigated the differences in response to PEG/RBV between each genotype and examined the efficacy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Propensity Score

Share to Ribavirin

Source

Identifiers

PMID: 25091289
DOI: 10.1111/jgh.12706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.PMID 25091289Read ↗

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.Semantic proximity Read ↗

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.Semantic proximity Read ↗

Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.Semantic proximity Read ↗

Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group.Semantic proximity Read ↗

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.Semantic proximity Read ↗

[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].Semantic proximity Read ↗

How to optimize current treatment of genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.Semantic proximity Read ↗

Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.Semantic proximity Read ↗

A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.Semantic proximity Read ↗

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.Semantic proximity Read ↗

Effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.